Learn About Geographic Atrophy
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Duke Eye Center
Glenn Jaffe is an Ophthalmologist and a General Surgeon in Durham, North Carolina. Dr. Jaffe is rated as an Elite provider by MediFind in the treatment of Geographic Atrophy. His top areas of expertise are Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Geographic Atrophy, Vitrectomy, and Trabeculectomy. Dr. Jaffe is currently accepting new patients.
Vitreous Retina Macula Consultants Of New York(Downtown)
Richard Spaide is an Ophthalmologist in New York, New York. Dr. Spaide is rated as an Elite provider by MediFind in the treatment of Geographic Atrophy. His top areas of expertise are Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Geographic Atrophy, Central Serous Chorioretinopathy, and Vitrectomy.
Duke Eye Center Arringdon
Eleonora Lad is an Ophthalmologist in Morrisville, North Carolina. Dr. Lad is rated as an Elite provider by MediFind in the treatment of Geographic Atrophy. Her top areas of expertise are Geographic Atrophy, Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, and Central Serous Chorioretinopathy. Dr. Lad is currently accepting new patients.
Summary: This study is for people who have geographic atrophy due to age-related macular degeneration (AMD). AMD happens when the macula, the light-sensitive layer at the back of the eye called the retina, becomes damaged and causes a person's central vision to worsen. Geographic atrophy is an advanced form of AMD where cells in the retina waste away and die. Over time this can lead to permanent loss of vi...
Summary: The main purpose of this study is to assess the ocular and systemic safety and tolerability of RO7669330 in participants with GA secondary to AMD in at least one eye in Part 1, or both eyes in Part 2, after multiple unilateral intravitreal (IVT) doses.